Recombinant Soluble Henipavirus Glycoprotein Preparation

Area of Science:

• Virology and Immunology
• Vaccine Development
• Protein Expression and Characterization

Background:

• Henipaviruses utilize two key envelope glycoproteins, attachment (G) and fusion (F) proteins, for cellular entry.
• These glycoproteins are critical targets for virus-neutralizing antibody responses, making them important for therapeutic and vaccine strategies.
• Recombinant expression of soluble glycoproteins (sG and sF) is crucial for maintaining native conformations and epitopes.

Purpose of the Study:

• To express and purify soluble tetrameric G and trimeric F glycoproteins from multiple henipavirus species.
• To characterize these recombinant glycoproteins for their suitability as antigens in vaccine and antibody therapeutic development.
• To generate monoclonal antibodies against henipavirus glycoproteins and assess their binding capabilities.

Main Methods:

• Utilized recombinant expression technologies to produce soluble G and F glycoproteins.
• Purified tetrameric sG and trimeric sF proteins from Hendra, Nipah, Cedar, and Ghana viruses.
• Employed a pan-henipavirus multiplex microsphere immunoassay to demonstrate antibody binding.

Main Results:

• Successfully produced and purified tetrameric sG and trimeric sF glycoproteins from Hendra, Nipah, Cedar, and Ghana viruses.
• These soluble glycoproteins retained native-like oligomeric conformations and epitopes.
• Generated monoclonal antibodies using these glycoproteins as immunizing antigens, confirming binding via immunoassay.

Conclusions:

• Soluble henipavirus G and F glycoproteins can be effectively produced using recombinant technologies.
• These recombinant proteins serve as valuable tools for developing henipavirus vaccines and antiviral antibody therapeutics.
• The generated monoclonal antibodies demonstrate broad reactivity, supporting their potential for diagnostic and therapeutic applications.